Hwang T, Brawley O. New federal incentives for diversity in clinical trials. N Engl J Med. 2022;387(15):1347–9.

Article  PubMed  Google Scholar 

Rothwell P. External validity of randomised controlled trials: “To whom do the results of this trial apply?” Lancet. 2005;365(9453):82–93.

Article  PubMed  Google Scholar 

Onakpoya I. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evid Based Med. 2018;23(1):6.

Article  PubMed  Google Scholar 

Lexchin J. Quality and quantity of data used by Health Canada in approving new drugs. Front Med. 2023;10:1299239.

Article  Google Scholar 

Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963–2004. CMAJ. 2005;172(6):765–7.

Article  PubMed  PubMed Central  Google Scholar 

Lexchin J. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Med. 2014;8(1):e14–9.

PubMed  PubMed Central  Google Scholar 

Government of Canada. Drug and health product submissions under review (SUR): new drug submissions completed. 2025. https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/submissions-under-review/new-drug-submissions-completed.html.

Rawson N, Kaitin K. Canadian and US drug approval times and safety considerations. Ann Pharmacother. 2003;37(10):1403–8.

Article  PubMed  Google Scholar 

Withdrawn 2.0. 2023. https://bioinformatics.charite.de/withdrawn_3/index.php.

Abraham J, Davis C. International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts. Soc Sci Med. 2022;255:113005.

Article  Google Scholar 

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open. 2018;8:e019759.

Article  PubMed  PubMed Central  Google Scholar 

McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decisionmaking. BMJ Open. 2014;4:e004221.

Article  PubMed  PubMed Central  Google Scholar 

Ninan B, Wertheimer A. Withdrawing drugs in the U.S. versus other countries. Innov Pharm. 2012;3(3):1–12.

Article  Google Scholar 

Onakpoya I, Heneghan C, Aronson J. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.

Article  PubMed  PubMed Central  Google Scholar 

Onakpoya I, Heneghan C, Aronson J. Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: an analysis of justification. Drug Saf. 2017;40(5):431–41.

Article  PubMed  Google Scholar 

Government of Canada. Notice of Compliance Search. 2025. https://health-products.canada.ca/noc-ac/?lang=eng.

Government of Canada. Drug Product Database online query. 2025. https://health-products.canada.ca/dpd-bdpp/.

Jefferys D, Leakey D, Lewis J, Payne S, Rawlins M. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol. 1998;45(2):151–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qureshi Z, Seoane-Vazquez E, Rodriguez-Monguiro R, Stevenson K, Szeinbach S. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Safe. 2011;20(7):772–7.

Article  Google Scholar 

Government of Canada. Recalls and safety alerts. 2025. https://recalls-rappels.canada.ca/en/search/site.

Lexchin J. New drugs and safety: what happened to New Active Substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172(21):1680–1.

Article  PubMed  Google Scholar 

Lexchin J. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. Br J Clin Pharmacol. 2014;79(5):847–59.

Article  Google Scholar 

Health Canada. Health Product Highlights Ottawa. 2021. https://www.canada.ca/content/dam/hc-sc/documents/services/publications/drugs-health-products/health-product-highlights-2021/health-product-highlights-2021-en.pdf.

US Department of Health & Human Services. Search orphan drug designations and approvals. Silver Spring, MD: U.S. Food and Drug Administration; 2025 https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm.

Government of Canada. Drug and health product portal: review decisions. 2025 https://dhpp.hpfb-dgpsa.ca/review-documents?search=&f%5B0%5D=content_type%3Asbd.

Equator Network. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. 2023 [updated March 6]. https://www.equator-network.org/reporting-guidelines/strobe/.

Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ. 2004;171(9):1027–8.

Article  PubMed  PubMed Central  Google Scholar 

Wooltorton E. Bayer pulls cerivastatin (Baycol) from market. CMAJ. 2001;165(5):632.

CAS  PubMed  Google Scholar 

Lexchin J. Orphan drug approval in Canada, 1999–2022: a cross-sectional study. Int J Health Policy Manag. 2025 (in press).

Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215–20.

Article  PubMed  Google Scholar 

Issa A, Phillips K, Van Bebber S, Nidamarthy H, Lasser K, Haas J, et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Safe. 2007;2(3):177–85.

Article  CAS  Google Scholar 

Tibau A, Hwang T, Romano A, Borrell M, Gich I, Molto C, et al. Factors in time to full approval or withdrawal for anticancer medicines granted accelerated approval by the FDA. JAMA Netw Open. 2025;8(3):e252026.

Article  PubMed  PubMed Central  Google Scholar